Genetically modified yeasts for the production of homogenous glycoproteins
AssigneeGlycode
InventorsChristophe Javaud, Vincent Carre
Life of this patent
Estimating the term…
Abstract
The present application relates to genetically modified yeasts for the production of glycoproteins having optimized and homogeneous glycan structures. These yeasts comprise an inactivation of the Och 1 gene, the integration by homologous recombination, into an auxotrophic marker, of an expression cassette comprising a first promoter, and an open reading frame comprising the coding sequence for an α-1,2-mannosidase I, and the integration of a cassette comprising a second promoter different from said first promoter and the coding sequence for an exogenous glycoprotein. These yeasts make it possible to produce EPO with an optimized and 98% homogeneous glycosylation.
Claims27
Genetically modified yeast cells, capable of producing glycoproteins having homogeneous glycans comprising the Man5GlcNac2 structure, said yeast cells comprising the following modifications:
- a) inactivation of the Och1 gene coding for α1,6-mannosyl transferase by insertion by homologous recombination of a heterologous sequence coding for a gene of resistance to an antibiotic (delta-Och1 strain);
- b) integration by homologous recombination into an auxotrophy marker of an expression cassette comprising a promoter selected from pGAP, pGAL1, PGK, TEF, adh1, nmt 1, SV40, PMA1, CaMV, pet56 of S. cerevisiae or S. pombe, and ADH2 having the sequence SEQ ID Nos. 16-26 respectively, an open reading phase comprising the sequence coding for an α-1-2 mannosidase I comprising a targeting sequence in the endoplasmic reticulum or Golgi apparatus and a terminator of the transcription;
- and
- c) integration by homologous recombination into an auxotrophy marker of an expression cassette comprising a promoter selected from pGAP, pGAL1, PGK, TEF, adh1, nmt 1, SV40, PMA1, CaMV, pet56 of S. cerevisiae or S. pombe, and ADH2 having the sequence SEQ ID Nos. 16-26 respectively, said promoter in c) being different from the promoter in b), an open reading phase comprising the sequence coding for an exogenous glycoprotein to be produced and a terminator of the transcription,
- wherein the yeast cells are Saccharomyces cerevisiae or Schizosaccharomyces pombe.
A pharmaceutical composition comprising EPO as an active ingredient, said EPO having more 90% of the structure:
- NANA2Gal2GlcNAc2Man3GlcNAc2 or NANA2Gal2GlcNAc2Man3(Fuc)GlcNAc2.
Dependencies are inferred from the claim text.